Skip to main content
. 2021 Jul 10;11(7):651. doi: 10.3390/jpm11070651

Figure 2.

Figure 2

The PFS over time according to sLAG3 value. Figure 2 shows the PFS over time (expressed in months after the start of treatment) in patients with/without an LAG3 value higher than the median. The number of patients at risk is also indicated. PFS refers to progression-free survival; 377 is the median value of LAG3, expressed in pg/mL; the blue line represents OS in patients with sLAG3 > 377 pg/mL, and the yellow line represents OS in patients with sLAG3 ≤ 377 pg/mL; the shaded bands represent the confidence intervals at each time point. The table under the figure indicates the number of subjects in each group (i.e., sLAG3 > 377 or ≤377 pg/mL) at baseline (0) or at 5, 10, or 15 months after the beginning of treatment. p = p-value; significant p-values are indicated in bold.